300+ investors in your industry, stage, and region Get
Any industry
Artificial Intelligence
Google
EdTech
Clean Energy
Retail
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Organic Food
Email
Fitness
CleanTech
Energy
Health Care
Machine Learning
Agriculture (AgTech)
Marketplace
Gaming
Facebook
Blockchain
B2B
Social Network
Big Data
Video Games
Education
Wellness
Medical Device
Mobile
Construction
Automotive
Legal
Sports
eSports
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Theatre
Recruiting
Crowdfunding
Web3
Medical
Fashion
Social
Venture Capital
Infrastructure
Beauty
Celebrity
Cannabis
Climate
LGBT
Publishing
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Music
Real Estate
Art
Sporting Goods
Digital Media
Finance
Manufacturing
FinTech
Social Media
Financial Services
Franchise
Non Profit
Mobile Advertising
Internet
Android
Biotech
Proptech
Sustainability
Hardware
Transportation
Impact
Enterprise
Community
Media (Entertainment)
Any country
Burkina Faso
South Korea
Africa
LATAM
Singapore
Brazil
Saudi Arabia
Oceania
Greece
Gibraltar
Norway
Liberia
Mexico
Taiwan
Sweden
Zambia
Puerto Rico
Tunisia
Russian Federation
Togo
Tajikistan
Zimbabwe
Nigeria
Guinea
Nepal
Iran
Kyrgyzstan
Pakistan
Isle of Man
Oman
Romania
New Zealand
Cameroon
Colombia
Australia
China
Sri Lanka
Armenia
Costa Rica
Switzerland
Czech Republic
Kenya
Cayman Islands
Kuwait
Kazakhstan
Jamaica
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uganda
Turkey
Uzbekistan
Venezuela
Guatemala
Seychelles
Malawi
Moldova
Botswana
United Kingdom
Japan
South Africa
Egypt
France
Georgia
Denmark
Croatia
Hong Kong
Ghana
Iraq
Mali
Morocco
Myanmar
Latvia
Malaysia
Poland
Philippines
Portugal
Sierra Leone
Rwanda
El Salvador
Senegal
Thailand
Uruguay
Tanzania
India
Germany
Canada
Ireland
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Cyprus
Qatar
United Arab Emirates
Spain
Europe
Angola
Argentina
Bangladesh
Barbados
Belgium
Ethiopia
Jordan
Austria
Azerbaijan
Ecuador
Bulgaria
Bahrain
Bahamas
Faroe Islands
Jersey
Estonia
Bolivia
Algeria
Belize
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Cambodia
Lithuania
Liechtenstein
Lebanon
Mongolia
San Marino
Peru
Slovenia
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotech Startup Investors in Europe (July 2026)

The most active venture capital funds and angel investors investing in Europe Biotech startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Europe Biotech startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Bpifrance
VC Fund
84 France, United States, Switzerland Seed, Series A Software, Information Technology, Health Care $726k–$34M
SOSV
VC Fund
80 United States, India, United Kingdom Seed, Convertible Note, Pre-Seed Biotechnology, Health Care, Software
Sofinnova Partners
VC Fund
73 France, United States, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $6.6M–$109M
UK Innovation & Science Seed Fund
VC Fund
60 United Kingdom, United States Seed, Series A Biotechnology, Health Care, Medical $458k–$14M
HTGF (High-Tech Gruenderfonds)
VC Fund
57 Germany, Switzerland, United States Seed, Series A Software, Biotechnology, Information Technology $1.1M–$33M
Scottish Enterprise
VC Fund
55 United Kingdom, United States, Switzerland Grant, Seed Biotechnology, Software, Health Care $119k–$4.3M
Novo Holdings
VC Fund
53 United States, Denmark, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $9M–$135M
Oxford Science Enterprises
VC Fund
45 United Kingdom, United States, Finland Seed, Series A, Series B Health Care, Biotechnology, Software $1.3M–$168M
Parkwalk Advisors
VC Fund
44 United Kingdom, United States, Philippines Seed, Series A, Series B Biotechnology, Health Care, Software $1.1M–$46M
SFC Capital
VC Fund
36 United Kingdom, United States, Canada Pre-Seed, Seed Artificial Intelligence, Software, Information Technology $127k–$2M
Kurma Partners
VC Fund
35 France, Switzerland, Spain Series A, Seed, Series B Health Care, Biotechnology, Medical $2.3M–$95M
Oxford Technology Management
VC Fund
35 United Kingdom, United States Seed, Series A Biotechnology, Health Care, Software $33k–$7.9M
Seventure Partners
VC Fund
34 France, United States, Germany Series A, Series B Biotechnology, Health Care, Software $3.1M–$65M
Boehringer Ingelheim Venture Fund
VC Fund
32 United States, Germany, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $1.8M–$50M
Enterprise Ireland
VC Fund
30 Ireland, United States, United Kingdom Seed, Series A Software, Information Technology, Health Care $494k–$12M
Jonathan Milner
Angel
30 United Kingdom, United States, Spain Seed, Series A, Series B Biotechnology, Health Care, Medical $537k–$56M
BioInnovation Institute
VC Fund
29 Denmark, Germany, Switzerland Convertible Note, Pre-Seed, Debt Financing Biotechnology, Medical, Health Care $500k–$5.2M
Scottish Investment Bank
VC Fund
29 United Kingdom, United States, France Seed, Series A Software, Biotechnology, Health Care $327k–$7M
Forbion Capital Partners
VC Fund
28 United States, United Kingdom, The Netherlands Series B, Series A, Series C Biotechnology, Health Care, Medical $16M–$176M
Centre for the Development of Industrial Technology (CDTI)
VC Fund
27 Spain, United States, France Grant, Seed Biotechnology, Health Care, Software $157k–$16M
Future Planet Capital
VC Fund
27 United Kingdom, United States, Spain Seed, Convertible Note Biotechnology, Health Care, Software $670k–$7.3M
GO CAPITAL
VC Fund
27 France, Canada, Israel Seed, Series A Biotechnology, Software, Health Care $549k–$13M
Catapult Ventures
VC Fund
27 United Kingdom, United States, Israel Seed, Series A Health Care, Biotechnology, Medical $150k–$26M
Epidarex Capital
VC Fund
26 United Kingdom, United States, Germany Series A, Seed, Series B Biotechnology, Health Care, Therapeutics $531k–$55M
Mercia Fund Managers
VC Fund
26 United Kingdom, United States, Hungary Seed, Series A Software, Health Care, Biotechnology $196k–$14M
M Ventures
VC Fund
26 United States, United Kingdom, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2.4M–$100M
Development Bank of Wales
VC Fund
25 United Kingdom, Australia, United States Seed, Debt Financing Software, Health Care, Biotechnology $18k–$4.1M
Chalmers Ventures AB
VC Fund
23 Sweden Pre-Seed, Seed Software, Biotechnology, Information Technology $5k–$2.7M
Archangels
VC Fund
23 United Kingdom, United States Seed, Series A Software, Health Care, Biotechnology $1.3M–$8.3M
Karista
VC Fund
23 France, United States, Finland Seed, Series A, Series B Software, Biotechnology, Health Care $713k–$33M
Northstar Ventures
VC Fund
23 United Kingdom, United States, Indonesia Seed, Series A Software, Health Care, E-Commerce $39k–$10M
Elaia
VC Fund
23 France, United States, Spain Seed, Series A, Series B Software, Artificial Intelligence, Information Technology $1.1M–$50M
Meusinvest (Noshaq)
VC Fund
22 Belgium, France, Germany Series A, Seed Biotechnology, Health Care, Medical $137k–$16M
IP Group
VC Fund
22 United Kingdom, United States, Australia Seed, Series A Health Care, Biotechnology, Therapeutics $393k–$23M
HealthCap
VC Fund
21 United States, Sweden, France Series B, Series A Biotechnology, Health Care, Medical $5.7M–$92M
AlbionVC
VC Fund
21 United Kingdom, United States, France Series A, Seed Software, Information Technology, Health Care $2.2M–$20M
MIG Capital
VC Fund
21 Germany, France, Austria Series A, Series B Biotechnology, Health Care, Therapeutics $1.6M–$54M
Omnes Capital
VC Fund
21 France, Germany, United States Series A, Series B Software, Biotechnology, Health Care $3.5M–$53M
Oxford Capital
VC Fund
21 United Kingdom, United States, France Seed, Series A Software, Health Care, Biotechnology $1.5M–$16M
AdBio partners
VC Fund
20 France, Spain, Belgium Seed, Series A Biotechnology, Health Care, Pharmaceutical $2.2M–$37M
Auriga Partners
VC Fund
20 France, United States, Switzerland Series B, Series A Biotechnology, Health Care, Medical $2.2M–$33M
O2h Ventures
VC Fund
20 United Kingdom, Hungary Seed, Series A Biotechnology, Health Care, Pharmaceutical $603k–$25M
Octopus Ventures
VC Fund
19 United Kingdom, United States, Germany Series A, Seed, Series B Software, Health Care, Artificial Intelligence $2.1M–$48M
GM&C Life Sciences Fund
VC Fund
19 United Kingdom, Italy, Germany Seed, Series A Health Care, Biotechnology, Medical $65k–$4.1M
Deepbridge Capital
VC Fund
19 United Kingdom, Australia, Singapore Seed, Series A Health Care, Biotechnology, Medical $152k–$15M
Industrifonden
VC Fund
19 Sweden, United States, Denmark Series A, Seed Biotechnology, Software, Information Technology $1.3M–$21M
Idinvest Partners
VC Fund
19 France, United States, Spain Series B, Series A Biotechnology, Software, Health Care $3.3M–$66M
Cambridge Innovation Capital
VC Fund
19 United Kingdom, United States, Ireland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2M–$73M
Eos
VC Fund
18 United Kingdom, Ireland, United States Seed, Series A Biotechnology, Health Care, Medical $1.4M–$47M
Newable Private Investing
VC Fund
18 United Kingdom, United States Seed, Series A Software, Health Care, Biotechnology
Access all 50 investors in Europe Biotech startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Bpifrance
VC Fund · Maisons-alfort, Ile-de-France, France · 84 investments in Europe Biotech startups

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: France, United States, Switzerland

Investor stats

  • Total investments: 1273
  • Round size: Seed $726k–$6.5M; Series A $2.7M–$34M
  • Lead/follow: 25% lead, 75% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • AQEMIA — Aqemia is an in silico drug discovery start-up, whose ambition is to discover rapidly more innovative therapeutic molecules with better chances of success.
  • EG 427 — EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
  • AI-Stroke — Developer of an artificial intelligence-powered mobile application designed to assist in pre-CT/MRI stroke diagnostics. The company offers a platform that guides first responders and patients through relevant exercises for stroke detection, captures and analyzes video data, and leverages the world's largest proprietary stroke patientvideo dataset (20,000 videos and 6 million images), enabling patients with a diagnosis and outcomes by reducing delays in treatment for stroke, increasing the number of treatment procedures, and recuding the rehab costs.
Show all investments...

SOSV
VC Fund · Princeton, New Jersey, United States · 80 investments in Europe Biotech startups, 75 in the past 12 months

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Convertible Note, Pre-Seed
  • Geography: United States, India, United Kingdom

Investor stats

  • Total investments: 1482
  • Lead/follow: no public data

Portfolio highlights

  • MixRift — MIXRIFT - game developers specialized in Mixed Reality
  • unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
  • Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Show all investments...

Sofinnova Partners
VC Fund · Paris, Ile-de-France, France · 73 investments in Europe Biotech startups

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: France, United States, United Kingdom

Investor stats

  • Total investments: 319
  • Round size: Series A $6.6M–$70M; Series B $10M–$109M; Series C $12M–$100M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: Likely still investing — raised $200M in 2023

Portfolio highlights

  • Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
  • GFBiochemicals — GFBiochemicals is the only company to produce levulinic acid at commercial scale directly from biomass.In 2008, a group of biobased chemical experts saw the significant potential of levulinic acid to replace petroleum-based products across a range of market sectors. GFBiochemicals was founded to develop the production technology needed for thisrevolution in chemicals and biofuels.GFBiochemicals demonstrated these breakthrough technologies in the Caserta plant, in partnership with the University of Pisa and the Polytechnic University of Milan. This commercial-scale plant was retrofitted with new conversion, recovery and purification technology.
  • Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
Show all investments...

UK Innovation & Science Seed Fund
VC Fund · Harwell, Oxfordshire, United Kingdom · 60 investments in Europe Biotech startups

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 136
  • Round size: Seed $458k–$5.9M; Series A $2.9M–$14M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: May invest from a new fund soon — last raise in 2014

Portfolio highlights

  • MFX — MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies.
  • Silveray — Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market.
  • Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
Show all investments...

HTGF (High-Tech Gruenderfonds)
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 57 investments in Europe Biotech startups

High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Information Technology
  • Stage:Seed, Series A
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 587
  • Round size: Seed $1.1M–$7.3M; Series A $3.5M–$33M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: Likely still investing — raised $522M in 2022

Portfolio highlights

  • Selfapy — Selfapy offers a therapy support tool that helps recognize negative patterns of thought and train new behavior. Selfapy is your guided, self-help online course against depression with a personal psychologist as a companion.
  • Verovaccines — VEROVACCiNES discovers and develops innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate subunit marker vaccines. This technology has been validated by demonstrating protection of several target animal species against different viral diseases(proof-of-concept).VEROVACCiNES GmbH is a spin-off company of the Martin Luther University Halle-Wittenberg, Germany in 2017. The company exclusively took over IP, brand, team, products and know-how from the former BMBF GO-Bio-funded VEROVACCiNES project at Halle University. VEROVACCiNES GmbH is eligible for follow-up phase 2 funding from the same BMBF GO-Bio program. They cooperate closely with veterinary pharmaceutical companies, universities and research institutes, and they are eager to initiate new collaborations.
  • OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Show all investments...

Scottish Enterprise
VC Fund · Glasgow, Glasgow City, United Kingdom · 55 investments in Europe Biotech startups

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Grant, Seed
  • Geography: United Kingdom, United States, Switzerland

Investor stats

  • Total investments: 362
  • Round size: Seed $375k–$3.9M; Grant $119k–$4.3M
  • Lead/follow: 37% lead, 63% follow

Portfolio highlights

  • KubeNet — We are KubeNet - a multi-award winning technology solutions provider based in Glasgow. Whether it's Managed IT, IT Support, Cloud, Connectivity, Voice or Cyber Security, we're by your side as your trusted technology partner.
  • Cumulus Oncology — Cumulus Oncology develops anti-cancer therapies for clinical settings in areas of high unmet need. We target key pathways to improve the efficacy and outcomes of current and experimental therapies. Cumulus has the backing of a successful entrepreneur in the oncology field and is led by a team of senior professionals and industry partners fromacross the drug discovery and development sector. Together, we offer a wealth of experience and deep insights into optimum approaches for improved cancer patient outcomes.
  • Smart Green Shipping — smart green shipping alliance. economically, socially and environmentally superior shipping solutions.
Show all investments...

Novo Holdings
VC Fund · Hellerup, Hovedstaden, Denmark · 53 investments in Europe Biotech startups

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Denmark, United Kingdom

Investor stats

  • Total investments: 351
  • Round size: Series A $9M–$125M; Series B $13M–$135M; Series C $30M–$118M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: May invest from a new fund soon — raised $165M in 2018

Portfolio highlights

  • Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
  • IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
  • Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Show all investments...

Oxford Science Enterprises
VC Fund · Oxford, Oxfordshire, United Kingdom · 45 investments in Europe Biotech startups

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Software
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Finland

Investor stats

  • Total investments: 178
  • Round size: Seed $1.3M–$12M; Series A $6.3M–$49M; Series B $13M–$168M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: Likely still investing — raised $327M in 2022

Portfolio highlights

  • AlveoGene — Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy
  • Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
  • Caudal Energy — Porpoise Power develops a tidal energy system using oscillating hydrofoil technology inspired by dolphin swimming mechanics.
Show all investments...

Parkwalk Advisors
VC Fund · London, England, United Kingdom · 44 investments in Europe Biotech startups

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Philippines

Investor stats

  • Total investments: 277
  • Round size: Seed $1.1M–$5M; Series A $1.6M–$13M; Series B $2M–$46M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: Likely still investing — fund raised in 2024

Portfolio highlights

  • Paragraf — We Work to Develop Innovative and Useful End Products from Novel Materials. Our Analogue Sensors Are Designed to Provide Accurate Field Gradient Mapping & Alignment.
  • Psyomics — Technology to support better mental health assessment - accelerating patients to the right care pathway, first time.
  • PredictImmune — Pragmatic play menciptakan demo slot x500 yang merupakan slot online gratis. Nikmati slot demo pragmatic gacor gampang menang di demo pragmatic jamin gacor.
Show all investments...

SFC Capital
VC Fund · London, England, United Kingdom · 36 investments in Europe Biotech startups

Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Software, Information Technology
  • Stage:Pre-Seed, Seed
  • Geography: United Kingdom, United States, Canada

Investor stats

  • Total investments: 489
  • Round size: Seed $127k–$2M; Pre-Seed $164k–$839k
  • Lead/follow: 36% lead, 64% follow
  • Last fund: May invest from a new fund soon — raised $1.9M in 2019

Portfolio highlights

  • Neubond — Neubond develops wearable devices for stroke mobility rehabilitation. These devices provide autonomous assistance and therapy during daily activities, integrating rehabilitation into the patient's daily life regardless of their motor capabilities. Neubond's solutions are designed to be intuitive and effective, aiming to improve thequality of life for individuals undergoing rehabilitation.
  • Sages — Biodegradeable, non-polluting, low-impact and vibrant dyes extracted from food waste.
  • Traknova — Traknova provides an AI-powered fleet management platform that helps companies track, manage, and protect vehicles and mobile assets. The platform offers real-time GPS tracking, live monitoring, and telematics data to give operators constant visibility over fleet movements and status. Users can access an intuitive dashboard with historical tripinformation, engine status, and alerts for events such as geofence breaches or unauthorized use. Traknova also supports integrated hardware, including tracking devices and online cameras, to strengthen asset security and streamline recovery when issues arise. The system is designed for fleets across industries, such as service businesses and vehicle rental operators, that need clearer scheduling, better time management, and improved operational control. By consolidating these tools into one platform, Traknova enables data-led fleet planning and day-to-day decision-making.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Kurma Partners
VC Fund · Paris, Ile-de-France, France · 35 investments in Europe Biotech startups

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Seed, Series B
  • Geography: France, Switzerland, Spain

Investor stats

  • Total investments: 138
  • Round size: Seed $2.3M–$17M; Series A $3.8M–$95M; Series B $12M–$72M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • EvlaBio — EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical).
  • AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
  • DAMAE Medical — Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis.
Show all investments...

Oxford Technology Management
VC Fund · Oxford, Oxfordshire, United Kingdom · 35 investments in Europe Biotech startups

Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 109
  • Round size: Seed $33k–$2.1M; Series A $786k–$7.9M
  • Lead/follow: 7% lead, 93% follow
  • Last fund: May invest from a new fund soon — last raise in 2012

Portfolio highlights

  • OrganOx — OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.
  • CryoLogyx — CryoLogyx Ltd. trading as CryoLogyx registered in England and Wales 13078280. VAT registered 373846855. Our registered office address is CryoLogyx Ltd, The Venture Centre, Sir William Lyons Road, Coventry, CV4 7EZ.
  • Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
Show all investments...

Seventure Partners
VC Fund · Paris, Ile-de-France, France · 34 investments in Europe Biotech startups

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series A, Series B
  • Geography: France, United States, Germany

Investor stats

  • Total investments: 239
  • Round size: Series A $3.1M–$27M; Series B $3.4M–$65M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • ErVimmune — Our team is focused on bringing breakthrough immunotherapies in unmet medical needs for cancer patients. Check our work!
  • Kainova Therapeutics — Domain Therapeutics is a biopharmaceutical company focused on GPCR in immuno-oncology. Discover more than you think on our innovative cancer treatments tackling GPCR mediated-immunosuppression
  • BAOUW / Outdoor Organic Nutrition — A raw, healthy, and natural diet made up of energy gels, energy bars, and energy fruit purees.
Show all investments...

Boehringer Ingelheim Venture Fund
VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 32 investments in Europe Biotech startups

Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Germany, Switzerland

Investor stats

  • Total investments: 101
  • Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
  • Lead/follow: 48% lead, 52% follow
  • Last fund: May invest from a new fund soon — raised $250M in 2018

Portfolio highlights

  • Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
  • ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
  • Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Show all investments...

Enterprise Ireland
VC Fund · Dublin, Dublin, Ireland · 30 investments in Europe Biotech startups

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: Ireland, United States, United Kingdom

Investor stats

  • Total investments: 633
  • Round size: Seed $494k–$3.3M; Series A $2.2M–$12M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: May invest from a new fund soon — raised $1.1M in 2021

Portfolio highlights

  • Revive Active — Revive Active health supplement is the only brand that unlocks your abundant natural energy to maximize the lifestyle you want because it’s a supplement that does not compromise on amount or quality but is abundant with fantastic ingredients. Revive Active Health Supplement is a high quality blend of 26 ingredients delivered in one convenientsachet. The unique blend of vitamins and minerals combine to provide a multitude of health benefits including natural sustained energy without the use of sugar and caffeine. The revolutionary product also brings two key Nobel prize-winning ingredients together for the first time. The combined inclusion of Coenzyme Q10 and L-Arginine further improves Revive Active’s ability to enhance energy and vitality and support a healthy immune system in regular consumers all for as little as a cup of coffee per day.Unlike traditional fish oil supplements, Revive Krill Oil is an extremely bioavailable source of EPA and DHA. Key to the enhanced absorption is the unique structure of the omega-3s. Fish oil omega-3s are found in a triglyceride form, which repel water impairing absorption in the digestive tract. Krill oil is found in a phospholipid form which attracts water promoting fast and efficient absorption. This helps deliver the essential omega-3s to the places you need it most.
  • Code Institute — Join our accredited online programs in AI, Data Science, & Full Stack Development. 98% of grads employed in 12 months. Learn from experts & get hired by top tech companies.
  • Irish Bioeconomy Foundation — The Irish Bioeconomy Foundation was founded to establish a fora of industry, academia & policy leaders around Ireland's emerging bioeconomy
Show all investments...

Jonathan Milner
Angel · Cambridge, Massachusetts, United States · 30 investments in Europe Biotech startups

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Spain

Investor stats

  • Total investments: 61
  • Round size: Seed $537k–$25M; Series A $4.1M–$50M; Series B $1.6M–$56M
  • Lead/follow: 20% lead, 80% follow

Portfolio highlights

  • Quibim — Quibim builds AI tools that turn MRI, CT and PET data into actionable predictions for hospitals and biopharma. Trusted in 230+ centers worldwide.
  • Nuclera — Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered totake control of biology through streamlined access to a next-day supply of proteins and genes.
  • 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
Show all investments...

BioInnovation Institute
VC Fund · Copenhagen, Hovedstaden, Denmark · 29 investments in Europe Biotech startups

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Convertible Note, Pre-Seed, Debt Financing
  • Geography: Denmark, Germany, Switzerland

Investor stats

  • Total investments: 87
  • Round size: Pre-Seed $516k–$5.2M; Debt Financing $533k–$1.4M; Convertible Note $500k–$1.5M
  • Lead/follow: 92% lead, 8% follow

Portfolio highlights

  • Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
  • Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
  • metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Show all investments...

Scottish Investment Bank
VC Fund · Glasgow, Glasgow City, United Kingdom · 29 investments in Europe Biotech startups

Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, France

Investor stats

  • Total investments: 208
  • Round size: Seed $327k–$3.1M; Series A $1.6M–$7M
  • Lead/follow: 11% lead, 89% follow
  • Last fund: May invest from a new fund soon — last raise in 2015

Portfolio highlights

  • Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
  • IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
  • Pneumagen — Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology.
Show all investments...

Forbion Capital Partners
VC Fund · Naarden, Noord-Holland, The Netherlands · 28 investments in Europe Biotech startups

Impacting the future of medicine.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, The Netherlands

Investor stats

  • Total investments: 200
  • Round size: Series A $19M–$176M; Series B $16M–$155M; Series C $19M–$113M
  • Lead/follow: 52% lead, 48% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
  • Inflazome — Situs gacor premium Megawin188 paling banyak di minati oleh semua kalangan karena pecah selayar tanpa henti dan memiliki tampilan yang sangat memanjakan mata.
  • Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Show all investments...

Centre for the Development of Industrial Technology (CDTI)
VC Fund · Madrid, Madrid, Spain · 27 investments in Europe Biotech startups, 33 in the past 12 months

The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Grant, Seed
  • Geography: Spain, United States, France

Investor stats

  • Total investments: 198
  • Round size: Seed $562k–$5.9M; Grant $157k–$16M
  • Lead/follow: 40% lead, 60% follow

Portfolio highlights

  • Xoople — Xoople operates as an earth intelligence company. Xoople powers the next generation of Earth data intelligence to achieve a systematic understanding of physical changes on the Earth’s surface.
  • Orga AI — Organ AI creates generative artificial intelligence that will help people. Its headquarters is located in Palma De Mallorca, Islas Baleares, Spain.
  • Golden Owl
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Future Planet Capital
VC Fund · London, England, United Kingdom · 27 investments in Europe Biotech startups

Brilliant Ideas. Brilliant People. Brilliant Minds.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Convertible Note
  • Geography: United Kingdom, United States, Spain

Investor stats

  • Total investments: 169
  • Round size: Seed $670k–$7.3M
  • Lead/follow: 7% lead, 93% follow
  • Last fund: Likely still investing — raised $23M in 2022

Portfolio highlights

  • Unloq AI — Unloq AI creates embedded, co-created technologies that link your business objectives to actual AI-enabled execution.
  • Nourished — At Nourished we create innovative. personalised nutrition stacks that are truly unique to you. Vegan, waste-free and always made to order.
  • NeoVac — NeoVac is creating revolutionary, unique and proprietary next-generation lipid nanoparticles to enable better RNA vaccines and treatments for various diseases.
Show all investments...

GO CAPITAL
VC Fund · Rennes, Bretagne, France · 27 investments in Europe Biotech startups

GO Capital is an independent management company and a major player in regional Seed and Venture Capital since 2003. With offices in Brittany, Pays de la Loire, Normandy, Centre-Val de Loire and the South of France, GO Capital contributes to the financing of responsible innovation in these regions. With a team of investors with complementarysectoral experience, we have a solid track-record in DeepTech. GO Capital has nearly 400 million euros under management, and mainly finances technology leaders in the digital and healthcare sectors and in the industry of the future.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Seed, Series A
  • Geography: France, Canada, Israel

Investor stats

  • Total investments: 137
  • Round size: Seed $549k–$6.6M; Series A $2.1M–$13M
  • Lead/follow: 39% lead, 61% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • AISPRID — AISPRID is a robotic company that manufactures autonomous robots for soft fruit picking.
  • Axomove — Axomove is an e-health app that specializes in video physical exercises.
  • NeoXperiences — NeoXperiences develops technological solutions that bring audiences together around fun and interactive experiences.
Show all investments...

Catapult Ventures
VC Fund · Leicester, Leicester, United Kingdom · 27 investments in Europe Biotech startups

The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Israel

Investor stats

  • Total investments: 105
  • Round size: Seed $150k–$5.6M; Series A $1.6M–$26M
  • Lead/follow: 25% lead, 75% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Path Robotics — We create manufacturing robots that autonomously scan, position, and weld your parts without the need for skilled welders or robot programmers.
  • Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
  • Anello Photonics — Anello Photonics is founded by pioneers in silicon photonics and inertial navigation. The patented Anello SiPhOG gyroscope offers an affordable mass-market sensor with true Optical Gyroscope performance. The company is headquartered in Silicon Valley and funded by leading venture capital firms.
Show all investments...

Epidarex Capital
VC Fund · Bethesda, Maryland, United States · 26 investments in Europe Biotech startups

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Seed, Series B
  • Geography: United Kingdom, United States, Germany

Investor stats

  • Total investments: 48
  • Round size: Seed $531k–$8.5M; Series A $2.6M–$38M; Series B $2.4M–$55M
  • Lead/follow: 48% lead, 52% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Leucid Bio — CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
  • Epsilogen — IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
  • Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Show all investments...

Mercia Fund Managers
VC Fund · Henley In Arden, Warwickshire, United Kingdom · 26 investments in Europe Biotech startups

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Hungary

Investor stats

  • Total investments: 136
  • Round size: Seed $196k–$2M; Series A $2M–$14M
  • Lead/follow: 67% lead, 33% follow
  • Last fund: May invest from a new fund soon — last raise in 2013

Portfolio highlights

  • Sen — Sen's vision is to democratize space using video to inform, educate, inspire and benefit all humanity. Sen's mission is to stream real-time videos from space to billions of people, gathering news and information about Earth and space and making it universally accessible.
  • Gentronix — Gentronix is a contract research organisation (CRO) providing a wide range of screening and safety services, including genetic toxicology screening and regulatory genotoxicity studies.
  • Haystack — Giving techies the tools to uncover, explore and discover the tech landscape with full anonymity - showcasing opportunities that match their interests, values and tech stack.
Show all investments...

M Ventures
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 26 investments in Europe Biotech startups

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Switzerland

Investor stats

  • Total investments: 171
  • Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
  • Lead/follow: 38% lead, 62% follow

Portfolio highlights

  • iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
  • Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
  • ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Show all investments...

Development Bank of Wales
VC Fund · Cardiff, Cardiff, United Kingdom · 25 investments in Europe Biotech startups

Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Debt Financing
  • Geography: United Kingdom, Australia, United States

Investor stats

  • Total investments: 238
  • Round size: Seed $360k–$3.3M; Debt Financing $18k–$4.1M
  • Lead/follow: 60% lead, 40% follow
  • Last fund: May invest from a new fund soon — raised $25M in 2018

Portfolio highlights

  • Forth — Forth are a group of clinical and digital experts who are passionate about healthcare. They’re part of a new breed of digital healthcare companies who are transforming people’s relationship with their health by using technology to give them more information and help them gain greater control.
  • Design and Supply — Design and Supply provides products and services primarily for the construction industry, offering Jansen-certified products and British SBD solutions. The company manufactures and supplies items, including steel doors. Additionally, Design and Supply caters to design enthusiasts by offering artwork, fine furniture, antiques, and decor.
  • Reacta Healthcare
Show all investments...

Chalmers Ventures AB
VC Fund · Göteborg, Vastra Gotaland, Sweden · 23 investments in Europe Biotech startups

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

Show more...

Investment focus

  • Industry: Software, Biotechnology, Information Technology
  • Stage:Pre-Seed, Seed
  • Geography: Sweden

Investor stats

  • Total investments: 211
  • Round size: Seed $290k–$2.7M; Pre-Seed $5k–$309k
  • Lead/follow: 46% lead, 54% follow

Portfolio highlights

  • Ambidex AB — helps food retailers create new revenue streams on their refrigeration systems by stabilizing the electricity grid.
  • Anferra — Anferra specializes in hydrometallurgy, utilizing methods for resource-efficient recycling of steel industry waste into iron chloride.
  • Arkeon Technologies — Arkeon Technologies is a deep-tech company developing innovative solutions for scalable superconducting quantum computing. Its patented technology enables precise post-fabrication tuning of qubit frequencies, improving quantum chip performance, yield, and reliability. By addressing key manufacturing challenges, Arkeon helps accelerate thedevelopment of large-scale quantum processors for next-generation computing.
Show all investments...

Archangels
VC Fund · Edinburgh, Edinburgh, City of, United Kingdom · 23 investments in Europe Biotech startups

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 85
  • Round size: Seed $1.3M–$3.9M; Series A $1.6M–$8.3M
  • Lead/follow: 54% lead, 46% follow

Portfolio highlights

  • BioCaptiva — BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
  • Bioliberty — Engineering the future of physical and occupational therapy.
  • Earth Blox — Earth Blox is a paradigm shift for teaching Earth observation skills to everyone from children to university students & professionals.
Show all investments...

Karista
VC Fund · Paris, Ile-de-France, France · 23 investments in Europe Biotech startups

Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Seed, Series A, Series B
  • Geography: France, United States, Finland

Investor stats

  • Total investments: 150
  • Round size: Seed $713k–$6.5M; Series A $1.2M–$23M; Series B $2.5M–$33M
  • Lead/follow: 16% lead, 84% follow

Portfolio highlights

  • CYSEC — Secure your sensitive data in the cloud and in the edge with ARCA Trusted OS and open the door to innovation with confidential computing.
  • Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
  • Acticor Biotech — Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Northstar Ventures
VC Fund · Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom · 23 investments in Europe Biotech startups

Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.

Show more...

Investment focus

  • Industry: Software, Health Care, E-Commerce
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Indonesia

Investor stats

  • Total investments: 199
  • Round size: Seed $39k–$2.2M; Series A $851k–$10M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • H2CHP — H2CHP's Free Piston Engine Technology enables your transition to green energy with the reliability & confidence of fuel flexibility.
  • NunaBio — NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities.
  • MySalesCoach — MySalesCoach offers Despite overwhelming evidence that sales coaching has the greatest impact on rep development and success, managers typically devote less than 5% of their time to coaching a team that craves and deserves coaching to reach their full potential.
Show all investments...

Elaia
VC Fund · Paris, Ile-de-France, France · 23 investments in Europe Biotech startups

Elaia is French venture capital firm focused on European digital and deep tech startups, from early stage to growth developpement. We back tech disruptors.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Information Technology
  • Stage:Seed, Series A, Series B
  • Geography: France, United States, Spain

Investor stats

  • Total investments: 218
  • Round size: Seed $1.1M–$9.9M; Series A $2.2M–$26M; Series B $4.2M–$50M
  • Lead/follow: 45% lead, 55% follow
  • Last fund: Likely still investing — fund raised in 2024

Portfolio highlights

  • Hema.to — Hema.to provides fully automated, AI-powered blood cancer detection suggestions based on flow cytometry data.
  • Nano Corp — Deep network analysis for everyone
  • Vibe — Advertise your brand on CTV & OTT content with Vibe's self-serve ad platform to target hundreds of channels & networks and reach millions of households.
Show all investments...

Meusinvest (Noshaq)
VC Fund · Liège, Liege, Belgium · 22 investments in Europe Biotech startups

Noshaq offers financial services to help businesses develop.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Seed
  • Geography: Belgium, France, Germany

Investor stats

  • Total investments: 77
  • Round size: Seed $137k–$6M; Series A $3.3M–$16M
  • Lead/follow: 9% lead, 91% follow

Portfolio highlights

  • TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
  • Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
  • Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Show all investments...

IP Group
VC Fund · London, England, United Kingdom · 22 investments in Europe Biotech startups

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Therapeutics
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Australia

Investor stats

  • Total investments: 194
  • Round size: Seed $393k–$7.6M; Series A $2M–$23M
  • Lead/follow: 21% lead, 79% follow
  • Last fund: May invest from a new fund soon — raised $125M in 2014

Portfolio highlights

  • Eight19 — Eight19, located in Cambridge, UK, develops and manufactures plastic photovoltaics for energy harvesting, for the internet of things and for off-grid applications. Through the innovative use of industry-standard, high-volume, roll-to-roll processes and solution-based organic photoactive materials, the company has a highly cost-effective route forscaling-up its technology to supply the largest markets. Eight19 is currently producing modules on a small scale for commercial partners with applications in indoor energy harvesting for wireless sensor and controllers, signage and display, and outdoor power for portable electronics. Our plastic PV modules benefit from flexibility, thinness, light-weight and robustness.
  • Slamcore — Positioning, mapping and perception | State-of-the-art visual SLAM turns sensor data into actionable, spatial understanding for your vehicles.
  • AudioScenic — THE NEW DIMENSION IN SOUND
Show all investments...

HealthCap
VC Fund · Stockholm, Stockholms Lan, Sweden · 21 investments in Europe Biotech startups

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A
  • Geography: United States, Sweden, France

Investor stats

  • Total investments: 130
  • Round size: Series A $5.7M–$85M; Series B $12M–$92M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: May invest from a new fund soon — raised $209M in 2019

Portfolio highlights

  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Neobiomics — Neobiomics is a Swedish life-science company that develops nutritional products for preterm infants and neonatal care. Its best-known products include ProPrems® and NeoMega36®.
  • Ultragenyx Pharmaceutical — Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.
Show all investments...

AlbionVC
VC Fund · London, England, United Kingdom · 21 investments in Europe Biotech startups

AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Series A, Seed
  • Geography: United Kingdom, United States, France

Investor stats

  • Total investments: 168
  • Round size: Seed $2.2M–$13M; Series A $3.8M–$20M
  • Lead/follow: 42% lead, 58% follow

Portfolio highlights

  • Umedeor — uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries. This enables sites to participate in dozens of programmes simultaneously without increasing overhead or burden on staff. For life science companies, uMed provides access toregulator quality data, where patients within those datasets can be compliantly re-engaged to support the aims of R&D and post-market teams
  • Xperiome — Match research-ready members to clinical and real-world studies, faster and smarter than ever before through data-driven insights into the rare disease experience.
  • Hussle — Gym membership with total flexibility. Gym passes to no contract gym memberships that you can use in thousands of gyms across the UK. Gym and swim wherever you want to. Stop and start whenever you like.
Show all investments...

MIG Capital
VC Fund · München, Bayern, Germany · 21 investments in Europe Biotech startups

MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B
  • Geography: Germany, France, Austria

Investor stats

  • Total investments: 96
  • Round size: Series A $2.2M–$40M; Series B $1.6M–$54M
  • Lead/follow: 45% lead, 55% follow
  • Last fund: May invest from a new fund soon — raised $70M in 2014

Portfolio highlights

  • NcodiN — The High Performance Computing (HPC) and ArtificiaI Intelligence (AI) era requires unprecedented computing capabilities. With this in view, industry is heading towards zettascale supercomputers, based on >100k processing units. Chiplets-based disaggregated processors and memory-centric computing architectures are taking over and require an ever more intensive communication between dies. Thus, today interconnect bottleneck is the main
  • GlassPoint Solar — GlassPoint provides solar steam generators to the oil and gas industry for applications such as Enhanced Oil Recovery. It replaces gas-fired steam generation with solar, GlassPoint can reduce EOR gas consumption by up to 80 percent. The company was founded in 2008 and headquartered in Fremont, California.
  • Zadient Technologies — Zadient produces semiconductor manufacturing materials that are critical for the entire silicon carbide (SiC) value chain
Show all investments...

Omnes Capital
VC Fund · Paris, Ile-de-France, France · 21 investments in Europe Biotech startups

Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Series A, Series B
  • Geography: France, Germany, United States

Investor stats

  • Total investments: 181
  • Round size: Series A $3.5M–$44M; Series B $4.4M–$53M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: May invest from a new fund soon — raised $403M in 2020

Portfolio highlights

  • VSORA — VSORA provides high performance companion solutions combining AI and signal processing to enable autonomous driving and ADAS
  • SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
  • Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Show all investments...

Oxford Capital
VC Fund · Oxford, Oxfordshire, United Kingdom · 21 investments in Europe Biotech startups

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, France

Investor stats

  • Total investments: 149
  • Round size: Seed $1.5M–$3.9M; Series A $3.2M–$16M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: May invest from a new fund soon — raised $56M in 2015

Portfolio highlights

  • Hometree — Keep yourself warm with Hometree, and try our no price hike promise. Compare our different boiler & home cover plans to see how you can save.
  • Archangel Lightworks — Archangel Lightworks is integrating space and air assets using laser communication.
  • Oxford Quantum Circuits — Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies.
Show all investments...

AdBio partners
VC Fund · Paris, Ile-de-France, France · 20 investments in Europe Biotech startups

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Seed, Series A
  • Geography: France, Spain, Belgium

Investor stats

  • Total investments: 32
  • Round size: Seed $2.2M–$18M; Series A $18M–$37M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: Likely still investing — raised $116M in 2021

Portfolio highlights

  • Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
  • ARTHEx Biotech — ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases.
  • Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Auriga Partners
VC Fund · Paris, Ile-de-France, France · 20 investments in Europe Biotech startups

Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A
  • Geography: France, United States, Switzerland

Investor stats

  • Total investments: 128
  • Round size: Series A $2.2M–$14M; Series B $3.8M–$33M
  • Lead/follow: 17% lead, 83% follow

Portfolio highlights

  • Availpro — D-EDGE empowers 17,000+ hotels to boost revenue with CRS, Booking Engine, Channel Manager, hospitality-focused websites & digital marketing solutions.
  • Nexthink — Discover what your employees need, see what they experience, know how they feel. Deliver IT that delights.
  • Bonitasoft — Bonita helps businesses automate workflows, boost efficiency, and turn complexity into a competitive edge. Unlock the power of process automation today!
Show all investments...

O2h Ventures
VC Fund · 20 investments in Europe Biotech startups

Transforming UK biotech breakthroughs into impact. o2h Ventures offers SEIS/EIS and growth-stage funds to back visionary teams from seed to clinical success.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Seed, Series A
  • Geography: United Kingdom, Hungary

Investor stats

  • Total investments: 39
  • Round size: Seed $603k–$7.5M; Series A $1.9M–$25M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Neurocentrx — Neurocentrx is a specialty pharma company, developing and in-licensing products in pain, palliative care, psychiatry and mood disorders.
  • BiVictriX Therapeutics — BiVictriX is a rapidly emerging UK biotechnology company applying a novel approach to develop safer, more effective cancer therapies.
  • Botanical Ventures Limited — Botanical Ventures Limited is a privately held company based in London, United Kingdom, and has been incorporated since 2017. The company brings together a diverse range of industries — including financial services, asset tokenization, mining operations, real estate, biotechnology, and botanical ventures — with a focus on building real-world valuethrough innovation and cross-sector expertise.Co-founded by Alexander Thomas Dover and Nicolas-André Borel, Botanical Ventures Limited operates with a vision to connect traditional industries with emerging technologies. While Alexander leads the company’s strategic direction, Nicolas-André serves as Chief Operating Officer, playing a key role in driving operational growth and cross-border initiatives.Registered under UK company law, Botanical Ventures is committed to long-term, sustainable development and creating new opportunities across both established and frontier markets.
Show all investments...

Octopus Ventures
VC Fund · London, England, United Kingdom · 19 investments in Europe Biotech startups

We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.

Show more...

Investment focus

  • Industry: Software, Health Care, Artificial Intelligence
  • Stage:Series A, Seed, Series B
  • Geography: United Kingdom, United States, Germany

Investor stats

  • Total investments: 387
  • Round size: Seed $2.1M–$13M; Series A $3.2M–$21M; Series B $7.5M–$48M
  • Lead/follow: 57% lead, 43% follow
  • Last fund: May invest from a new fund soon — raised $101M in 2019

Portfolio highlights

  • Turtl — Create personalized interactive content experiences that excite, engage and convert your audience with Turtl's intuitive content software.
  • Sprout.ai
  • Minimum — Take control of your organization's carbon accounting and management with granular, robust and auditable emissions data.
Show all investments...

GM&C Life Sciences Fund
VC Fund · Alderley Edge, Cheshire, United Kingdom · 19 investments in Europe Biotech startups

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, Italy, Germany

Investor stats

  • Total investments: 33
  • Round size: Seed $65k–$936k; Series A $1.8M–$4.1M
  • Lead/follow: 67% lead, 33% follow

Portfolio highlights

  • SurgaColl — SurgaColl Technologies is a medical device company developing novel tissue regeneration products for the surgical treatment of diseases of the bone, cartilage and other human tissue. Based on technology developed at the Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland (RCSI), headed by Professor Fergal O’Brien,the company aims to become a leader in the field of regenerative medical devices.
  • Acea Health — Acea Health is a digital healthcare company developing an application called Flynotes - a new digital consent platform. Flynotes analyses a number of factors, including the patient’s background, to deliver personalised risks and benefits. Flynotes aims to be the go-to solution for consent in healthcare. .
  • Nexus Labs (Surgical Teaching) — Nexus Labs is an interactive learning resource for medical students.
Show all investments...

Deepbridge Capital
VC Fund · Chester, Cheshire, United Kingdom · 19 investments in Europe Biotech startups

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, Australia, Singapore

Investor stats

  • Total investments: 86
  • Round size: Seed $152k–$2.6M; Series A $2M–$15M
  • Lead/follow: 72% lead, 28% follow
  • Last fund: Likely still investing — raised $1.4M in 2022

Portfolio highlights

  • HeadBox — HeadBox connects corporate event planners with 100,000+ unique, inspiring, iconic, and creative spaces worldwide for meetings and events.
  • Touch Biometrix — Welcome at Touch Biometrix. Find out more about The Future of Fingerprint Biometrics!
  • Spotlight Pathology — Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers.
Show all investments...

Industrifonden
VC Fund · Stockholm, Stockholms Lan, Sweden · 19 investments in Europe Biotech startups

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Information Technology
  • Stage:Series A, Seed
  • Geography: Sweden, United States, Denmark

Investor stats

  • Total investments: 194
  • Round size: Seed $1.3M–$6.2M; Series A $3.3M–$21M
  • Lead/follow: 40% lead, 60% follow

Portfolio highlights

  • Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
  • Peafowl Plasmonics — IOSBET menyediakan akses slot demo Pragmatic resmi dengan pilihan game terbanyak, pendaftaran mudah, sistem aman, serta pengalaman bermain nyaman tanpa risiko.
  • Trackpaw Scientific — Contributing to the development of safe and effective pharmaceuticals at increased speed and quality by digitalising the preclinical study landscape.
Show all investments...

Idinvest Partners
VC Fund · Paris, Ile-de-France, France · 19 investments in Europe Biotech startups

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Series B, Series A
  • Geography: France, United States, Spain

Investor stats

  • Total investments: 252
  • Round size: Series A $3.3M–$24M; Series B $7.8M–$66M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — raised $88M in 2021

Portfolio highlights

  • LumApps — LumApps is the only intranet packaged solution that enables employees to feel connected to their organization and engaged in their work from anywhere by delivering a modern, smart digital headquarters that empowers your employees to design a work experience that works for them.
  • Ornikar — Ornikar is an online driving school that offers radically cheaper, uncomplicated and faster offer to obtain a driving license.Ornikar relies on a network of state-qualified teachers to offer an apprenticeship in mobile driving at reduced prices. The cmpany is an an online driving school more in tune with the demand of current and futuregenerations.The company's mission is to make the driver's license exam cheaper and its learning more enjoyable.
  • Pretty Simple — Video games studio based in Paris, France. Makers of Criminal Case and Sorcery School.
Show all investments...

Cambridge Innovation Capital
VC Fund · Cambridge, Cambridgeshire, United Kingdom · 19 investments in Europe Biotech startups

As a team, we have a passion for science and its potential to drive change. Through our expertise and our position in one of the country's most powerful science and technology ecosystems, we're able to identify and support the most promising entrepreneurs in knowledge intensive businesses and help them achieve their vision.With our financial backing and expert guidance, we're excited to enable the pioneers in life sciences and deep tech to create world-leading companies whose unique ideas bring financial success and global impact.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United Kingdom, United States, Ireland

Investor stats

  • Total investments: 101
  • Round size: Seed $2.5M–$31M; Series A $2M–$73M; Series B $8.5M–$65M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Immutrin — Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils.
  • Trent AI — Trent AI creates AI applications and agent security management software. It aids in risk assessment and mitigation in systems utilizing autonomous or semi-autonomous software agents. The company's technology monitors agent activity across APIs, tools, and workflows. It continuously assesses security posture via iterative scanning andcontextual understanding of system architectures.
  • TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates
Show all investments...

Eos
VC Fund · Edinburgh, Edinburgh, City of, United Kingdom · 18 investments in Europe Biotech startups

Eos invests in, & commercialises, science & technology, from local seed-stage to global scale, with a focus on improving lives.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, Ireland, United States

Investor stats

  • Total investments: 42
  • Round size: Seed $1.4M–$11M; Series A $1.6M–$47M
  • Lead/follow: 60% lead, 40% follow

Portfolio highlights

  • Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
  • Nami Surgical — Nami Surgical provides robotic surgery technology solutions to enhance patient care while giving surgeons intuitive, high-performance moveable instruments.
  • Cumulus Oncology — Cumulus Oncology develops anti-cancer therapies for clinical settings in areas of high unmet need. We target key pathways to improve the efficacy and outcomes of current and experimental therapies. Cumulus has the backing of a successful entrepreneur in the oncology field and is led by a team of senior professionals and industry partners fromacross the drug discovery and development sector. Together, we offer a wealth of experience and deep insights into optimum approaches for improved cancer patient outcomes.
Show all investments...

Newable Private Investing
VC Fund · London, England, United Kingdom · 18 investments in Europe Biotech startups

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 102
  • Lead/follow: no public data

Portfolio highlights

  • Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
  • Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
  • EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology
Show all investments...

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotech Investors in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 48,091 investors investing in Europe Biotech startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists